Treatment Systems Processes and Devices Addressing Cerebral Vasospasm/Vasoconstriction

Abstract

Endovascular treatment of, for example, delayed cerebral vasospasm involves the placing of a microcatheter in the affected vessels followed by the teachings of the instant disclosure, which is clinically improved with comparison to slow infusion of a vasodilating compound. Systems, processes and self-expanding designed stents and stent-like members are featured and highlighted. The stents and stent-like members being retrieved, nothing is left in the vessel. Drug-eluting stents, resorbable stents and angiographically imageable coatings, including tantalum brushes over part or all of subject system components are also disclosed.

What is claimed is: 
     
         1 . A Kit, comprising, in combination:
 at least a guide catheter system;   at least a self-expanding sheath and retrievable stenting-means;
 Further comprising an elongated structure ranging to at least about 50 cm; 
 a plurality of cells being smaller cells disposed about the stenting-means, whereby radial force is maintained within a range that does not cause the vessel to recoil or vasoconstrict, and; 
 full digital surgical history data of the procedure and hard copy instructions for use. 
   
     
     
         2 . The Kit of  claim 1 , further comprising:
 instructions to maintain the retrievable stenting means in situ for a time determined by an update formula supplied by the full digital surgical data being interpreted.   
     
     
         3 . The Kit of  claim 2 , further comprising:
 instructions to maintain the retrievable stenting means in situ for at least about 5 minutes, in combination with resultory data driven instructions determined by a License practitioner along with Artificial Intelligence.   
     
     
         4 . The Kit of  claim 2 , further comprising:
 instructions to maintain the retrievable stenting means in situ for at least about 5 minutes, in combination with resultory data driven instructions determined by Artificial Intelligence.   
     
     
         5 . An improved vessel patency system, which comprises, in combination:
 A specialized stent-means/device for deployment in intracranial arteries experiencing vasospasm, in order to expand vessels to their optimal diameter and remain patent after the device is re-sheathed.   
     
     
         6 . The improved vessel patency system of  claim 16 , further comprising:
 the stent-means/device being self-expanding nitinol with small cells.   
     
     
         7 . The improved vessel patency system of  claim 17 , further comprising:
 said stent-means/device being self-expanding nitinol which adduces optimum control and radial force to mitigate/extenuate or prevent vasoconstriction/vasospasm by not Damaging the Extracellular Matrix of the vessel into which it is designed to be implanted.   
     
     
         8 . The improved vessel patency system of  claim 7 , further comprising:
 said stent-means/device being self-expanding nitinol and predetermined values for radial force being employed, whereby positioning is achieved and vessel re-coil lessened.   
     
     
         9 . The improved vessel patency system of  claim 8 , further comprising:
 a device ranging from approximately 2-6 mm in diameter and from at least about 20 cm to 50 cm in length.   
     
     
         10 . An improved kit including an optimized stent device for treating vasospasm, which comprises, in combination:
 a guide catheter system;   a self-expanding sheath and retrievable stent device;   the retrievable stent device being greater than at least about 50 cm long;   wherein the cells of the stent device are small and the radial force generated thereby is within a range that does not cause the vessel to re-coil or vasoconstrict.   
     
     
         11 . The improved kit of  claim 10 , said range being greater than the radial force of current devices such as the SOLITAIRE®, TREVO®, MINDFRAME 40® brands of stents, but less than the radial force of Percutaneous Transluminal Angioplasty (PTA) balloons such as the COMANECI® brand of balloon. 
     
     
         12 . A novel stent for addressing vasospasm for being lodged temporarily against the intima of a vessel, comprising, in combination:
 a vessel body up to and slightly above 50 cm in length;   Small cell size to spread forces applied to the same over the entire length of the stent;   a maximum number of contact points between the stent and the vessel surface; and;   a significantly increased radial force, limited by a threshold of not damaging the Extra-cellular Matrix (ECM) of the vessel intima, yet strong enough to stretch the Smooth Muscle Cells (SMC) to elastic deformity.   
     
     
         13 . A temporary stent-device for treating vasospasm, comprising: between 20 and 50 cm in length;
 and an open cell structure.   
     
     
         14 . The temporary stent-device of  claim 13 , deployed for at least 5 minutes during vasospasm treatment. 
     
     
         15 . A specialized stent having less radial force in proximal and distal ends to decrease potential for mechanical vessel wall alteration. 
     
     
         16 . The specialized stent of  claim 15 , whereby collagen fibers are not damaged, when deployed according to the procedures issued as claimed in U.S. Pat. No. 9,808,359. 
     
     
         17 . The specialized stent of  claim 16 , whereby vascular smooth muscle cells are stretched outside of being harmed when deployed according to the procedures issued as claimed in U.S. Pat. No. 9,808,359. 
     
     
         18 . The specialized stent of  claim 17 , whereby the extra cellular matrix is not damaged when deployed according to the procedures issued as claimed in U.S. Pat. No. 9,808,359. 
     
     
         19 . The specialized stent of  claim 18 , whereby less harm is done than with balloon angioplasty when deployed according to the procedures issued as claimed in U.S. Pat. No. 9,808,359. 
     
     
         20 . The specialized stent of  claim 19 , whereby the cell structure is open and close celled at distal and proximal ends respectively when deployed according to the procedures issued as claimed in U.S. Pat. No. 9,808,359.